May 14th 2012 - Edison Investment Research today published a report on Oxford BioMedica (OXB.L, LSE:OXB, LON:OXB) entitled "Solid LentiVector Safety". In summary, the report says:
LentiVector’s favourable safety profile is further supported by clinical data presented at ARVO 2012 from the ocular programmes. To date no adverse events related to the company’s LentiVector platform (four products in the clinic), nor administration methods, have been seen. Positive initial data from the Phase I trial of RetinoStat in wet AMD bodes well for partner Sanofi potentially exercising its option to license later this year. Option exercise is expected to be the next major catalyst, triggering double-digit million-dollar milestones and securing Oxford BioMedica’s cash position beyond Q113. This would also provide funds to run at least part of the Phase IIa/b ProSavin trial planned for 2013, which should advance ongoing deal discussions.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »